Overview of Antidepressant Use in Depressive Patients at dr. H. Soewondo Hospital
DOI:
https://doi.org/10.37287/picnhs.v7i1.2567Keywords:
antidepressants, depression, drug utilization, escitalopram, SSRIAbstract
Depression is a mental health condition marked by persistent sadness, reduced interest in daily activities, and impaired social and cognitive functioning, making effective treatment essential to improve outcomes and reduce harmful effects. This study aimed to describe the use of antidepressant medication among patients with depression in a regional general hospital. The study applied a descriptive quantitative design with a retrospective approach using medical record data of patients who met the inclusion criteria during the study period. A total of 209 patients were selected with the Slovin formula, and data were analyzed descriptively and presented as frequencies and percentages. The results showed that the most commonly used medication was escitalopram at 34.9 percent, followed by fluoxetine at 31.6 percent, and sertraline at 10.5 percent. Most patients were female at 60.3 percent, with the largest age group being 15 to 25 years at 31.1 percent. These findings indicate that antidepressant use was dominated by the selective serotonin reuptake inhibitor group, with escitalopram as the preferred therapy reflecting alignment with clinical treatment guidelines for depression.
References
Albert, P. R. (2015). Why is depression more prevalent in women? Journal of Psychiatry & Neuroscience, 40(4), 219–221. https://doi.org/10.1503/jpn.150205
American Psychiatric Association. (2020). Practice guideline for the treatment of patients with major depressive disorder (3rd ed.). American Psychiatric Association Publishing. https://doi.org/10.1176/appi.books.9780890424841
Auerbach, R. P., Mortier, P., Bruffaerts, R., Alonso, J., Benjet, C., Cuijpers, P., ... & WHO WMH-ICS Collaborators. (2018). WHO World Mental Health Surveys International College Student Project: Prevalence and distribution of mental disorders. Journal of Abnormal Psychology, 127(7), 623–638. https://doi.org/10.1037/abn0000362
Chisholm, D., Sweeny, K., Sheehan, P., Rasmussen, B., Smit, F., Cuijpers, P., & Saxena,
S. (2016). Scaling-up treatment of depression and anxiety: A global return on investment analysis. The Lancet Psychiatry, 3(5), 415–424. https://doi.org/10.1016/S2215-0366(16)30024-4
Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., ... & Geddes, J. R. (2018). Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis. The Lancet, 391(10128), 1357–1366. https://doi.org/10.1016/S0140-6736(17)32802-7
Cuijpers, P., Karyotaki, E., Reijnders, M., & Purgato, M. (2020). Meta-analyses and mega-analyses of the effectiveness of digital health interventions for mental health. Journal of Behavioral Therapy and Experimental Psychiatry, 68, 101615. https://doi.org/10.1016/j.jbtep.2020.101615
Dipiro, J. T., Talbert, R. L., Yee, G. C., Matzke, G. R., Wells, B. G., & Posey, L. M. (2015). Pharmacotherapy: A pathophysiologic approach (9th ed.). McGraw-Hill Education.
Duan, Y., Wang, Y., Wang, C., & Li, H. (2022). Long-term effectiveness and safety of fluoxetine in major depressive disorder: A systematic review. Frontiers in Psychiatry, 13, 842711. https://doi.org/10.3389/fpsyt.2022.842711
Iqbal, S., Gupta, S., Venkatarao, E., & Agarwal, V. (2020). Stress, anxiety, and depression among medical undergraduate students and their socio-demographic correlates. Indian Journal of Community Medicine, 45(1), 87–89. https://doi.org/10.4103/ijcm.IJCM_241_19
Lim, G. Y., Tam, W. W., Lu, Y., Ho, C. S., Zhang, M. W., & Ho, R. C. (2018). Prevalence of depression in the community from 30 countries between 1994 and 2014. Scientific Reports, 8, 2861. https://doi.org/10.1038/s41598-018-21243-x
Motta, R. W., & Link, J. (2021). The prevalence of depression: A global perspective. Psychology Research and Behavior Management, 14, 493–502. https://doi.org/10.2147/PRBM.S297673
Riskesdas. (2013). Riset kesehatan dasar 2013. Badan Penelitian dan Pengembangan Kesehatan, Kementerian Kesehatan Republik Indonesia. https://www.litbang.kemkes.go.id/laporan-riset-kesehatan-dasar-riskesdas/
Salk, R. H., Hyde, J. S., & Abramson, L. Y. (2017). Gender differences in depression in representative national samples: Meta-analyses of diagnoses and symptoms. Psychological Bulletin, 143(8), 783–822. https://doi.org/10.1037/bul0000102
Septyarini, S. R., Nugroho, R. A., & Prihandayani, P. (2021). Antidepressant prescribing patterns in a regional hospital in Indonesia. Pharmacology and Clinical Pharmacy Research, 6(2), 109–115. https://doi.org/10.15416/pcpr.v6i2.1234
Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press. https://doi.org/10.1017/CBO9781139087562
Uher, R., Perlis, R. H., Placentino, A., Dernovšek, M. Z., Henigsberg, N., Mors, O., ... & McGuffin, P. (2019). Depression symptom dimensions as predictors of antidepressant treatment outcome: Replicable evidence for interest–activity symptoms. Psychological Medicine, 49(3), 364–373. https://doi.org/10.1017/S0033291718001088
World Health Organization. (2018). mhGAP intervention guide for mental, neurological and substance use disorders in non-specialized health settings (Version 2.0). World Health Organization. https://apps.who.int/iris/handle/10665/250239
World Health Organization. (2023). Depression. https://www.who.int/news-room/fact-sheets/detail/depression
